Personalized treatment of immune-related adverse events — balance is required
- 16 June 2020
- journal article
- letter
- Published by Springer Science and Business Media LLC in Nature Reviews Clinical Oncology
- Vol. 17 (8), 517
- https://doi.org/10.1038/s41571-020-0400-4
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Moving towards personalized treatments of immune-related adverse eventsNature Reviews Clinical Oncology, 2020
- New therapeutic perspectives to manage refractory immune checkpoint-related toxicitiesThe Lancet Oncology, 2019
- A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapyJournal for ImmunoTherapy of Cancer, 2018
- A severe case of neuro-Sjögren’s syndrome induced by pembrolizumabJournal for ImmunoTherapy of Cancer, 2018
- JAK inhibition as a therapeutic strategy for immune and inflammatory diseasesNature Reviews Drug Discovery, 2017
- JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancerOncoImmunology, 2017
- Primary Resistance to PD-1 Blockade Mediated by JAK1/2 MutationsCancer Discovery, 2017
- Histopathology of drug rash with eosinophilia and systemic symptoms syndrome: a morphological and phenotypical studyBritish Journal of Dermatology, 2015